"[They] get to be extremely enabling, because it becomes a very clear and specific roadmap."

— Campbell Rogers, chief technology officer at stent maker Cordis, discussing FDA's new guidance on stent approval requirements, "New stent trials now must follow patients for 1.5 years,"

No Comments